
    
      This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of
      Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line
      Stage IV Non-Small Cell Lung Cancer (NSCLC).
    
  